IP Group returns to growth as Pfizer deal drives NAV rise

The university spinout investor posted a 13% increase in net asset value per share after Pfizer's acquisition of obesity drug developer Metsera IP Group PLC (LSE:IPO), the London-listed investor in university spinout companies, has reported a return to growth in 2025, with net asset value (NAV) per share rising 13% to 110.4 pence and total NAV reaching £975.1 million. The improvement follows a difficult 2024, when NAV per share fell 15% and the group posted a loss of £207 million.